🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Qiagen NV (QIA)

Frankfurt
Currency in EUR
Disclaimer
37.88
-0.45(-1.17%)
Closed
QIA Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected in 10 days
Fair Value
Day's Range
37.8838.43
52 wk Range
33.0143.17
Bid/Ask
38.05 / 38.39
Prev. Close
38.33
Open
38.43
Day's Range
37.88-38.43
52 wk Range
33.01-43.17
Volume
432
Average Volume (3m)
990
1-Year Change
-7.5%
Fair Value
Unlock
Fair Value Upside
Unlock
QIA Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
53.60
Upside
+42.50%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield
  • Qiagen Earnings, Revenue beat In Q2
    • ByInvesting.com
  • Qiagen Earnings, Revenue beat In Q1
    • ByInvesting.com
  • Qiagen Earnings, Revenue beat In Q4
    • ByInvesting.com
  • Qiagen Earnings, Revenue beat In Q3
    • ByInvesting.com
  • Qiagen Earnings, Revenue beat In Q1
    • ByInvesting.com
  • Qiagen Earnings, Revenue beat In Q4
    • ByInvesting.com

Qiagen NV Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a collaboration with the U.S. FBI. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Employees
5900
Market
Germany
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.